PAA’s lead candidate is Monepantel (MPL), a small molecule drug currently being developed as a novel, safe and potent treatment for cancer. One of monepantel’s key clinical attributes is its low toxicity as evidenced by its approved use in food chain animals and by PharmAust’s own Phase I trial.

PharmAust has completed Phase 1 clinical trials with monepantel in human and dog diagnosed with solid tumours. All trials achieved their primary clinical endpoints in terms of safety and reduction in key clinical biomarkers. The company has also initiated a Phase 2 pilot study in dogs diagnosed with Lymphoma.

PharmAust has also initiated a preclinical programme to screen its portfolio of proprietary aminoacetonitrile (AAD) compounds for anticancer activity. These novel compounds are related to but distinct from monepantel and have the potential to provide the company with a fully-proprietary oncology pipeline.